Sandoz in Biosimilars Pact with Just – Evotec Biologics
As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year strategic partnership with Just –Evotec Biologics, the Seattle, Washington-based US subsidiary of Germany’s Evotec, to develop and manufacture biosimilars.
